Jason P. Rhodes - 05 Jun 2026 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Reporting relationship: Director
Issuer ticker: DYN
Reported as of: 05 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2026, 17:13:25 UTC
Prior SEC filing: 06 May 2026
Next SEC filing: 26 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Ommer Chohan, Attorney-in-Fact

Key filing fact

Jason P. Rhodes filed Form 4 for Dyne Therapeutics, Inc. (DYN) on 09 Jun 2026.

Key facts

This page summarizes Jason P. Rhodes's Form 4 filing for Dyne Therapeutics, Inc. (DYN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2026, 17:13.

Change

Previous filing in this sequence was filed on 06 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001577014 Primary reporting owner

Rhodes Jason P

Relationship: Director
Address: C/O DYNE THERAPEUTICS, INC., 1560 TRAPELO ROAD, WALTHAM
Signature: /s/ Ommer Chohan, Attorney-in-Fact
Signature date: 09 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DYN transaction Derivative

Stock option (right to buy)

Award

Transaction value
Shares: +35,152
Change %
Price: $0.000000^*
Shares after: 35,152
Date: 05 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,152
Exercise price: $17.04
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

Footnote F2

The Reporting Person is a member of Atlas Venture Associates XI, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.